Quest Diagnostics Incorporated · NYSE:DGX
Quest Diagnostics — Q4 2023 Earnings Presentation
6 slides from Quest Diagnostics's earnings presentation, Feb 1, 2024
Slide 1: 2024 Guidance
2024 Guidance February 1, 2024
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure The statements in this presentation which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management’s current esti
Slide 3: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures As used in this presentation the term “reported” refers to measures under accounting principles generally accepted in the United States (“GAAP”). The term “adjusted” refers to non-GAAP operating performance measures that exclude special items such as restructuring
Slide 4: Guidance for Full Year 2024
Guidance for Full Year 2024 The company estimates full year 2024 guidance as follows: Low High Net Revenues $9.35 billion $9.45 billion Net Revenues increase 1.1% 2.1% Reported diluted EPS $7.69 $7.99 Adjusted diluted EPS $8.60 $8.90 Cash provided by operations Approximately $1.3 billion Capital e
Slide 5: 2024 Adjusted Diluted EPS Guidance Bridge
2024 Adjusted Diluted EPS Guidance Bridge ~$0.92-$1.18 ~($0.49)-($0.51) ~(0.05)-($0.07) ~($0.20) $8.71 $8.60-$8.90 ~($0.25) 2023 Base Business COVID-19 Weather Haystack Interest 2024 3 Adjusted Diluted Growth1 Revenue Decline Impact Dilution 2 Expense Adjusted Diluted EPS EPS 1. Base business growth
Slide 6: Non-GAAP Reconciliations
Non-GAAP Reconciliations The following table reconciles adjusted results to reported results under accounting principles generally accepted in the United States. Year ended Year ended December 31, December 31, 2024 2023 Low High Reported diluted EPS $7.49 $7.69 $7.99 Amortization of intangible ass
Quest Diagnostics — Q4 2023 Earnings Presentation on 6ix